Christina Abdel Shaheed1, Chris G Maher2, Kylie A Williams3, Richard Day4, Andrew J McLachlan5. 1. The George Institute for Global Health, Sydney, Australia2School of Medicine, Western Sydney University, Penrith, Australia. 2. Musculoskeletal Division, The George Institute for Global Health, Sydney, Australia4Sydney Medical School, University of Sydney, Sydney, Australia. 3. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia. 4. Department of Clinical Pharmacology, St Vincent's Hospital and St Vincent's Clinical School, University of New South Wales, Sydney, Australia7School of Medical Sciences, University of New South Wales, Sydney, Australia. 5. The George Institute for Global Health, Sydney, Australia8Centre for Education and Research on Ageing, Sydney, Australia.
Abstract
IMPORTANCE: Opioid analgesics are commonly used for low back pain, however, to our knowledge there has been no systematic evaluation of the effect of opioid dose and use of enrichment study design on estimates of treatment effect. OBJECTIVE: To evaluate efficacy and tolerability of opioids in the management of back pain; and investigate the effect of opioid dose and use of an enrichment study design on treatment effect. DATA SOURCES: Medline, EMBASE, CENTRAL, CINAHL, and PsycINFO (inception to September 2015) with citation tracking from eligible randomized clinical trials (RCTs). STUDY SELECTION: Placebo-controlled RCTs in any language. DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted data and assessed risk of bias. Data were pooled using a random effects model with strength of evidence assessed using the grading of recommendations assessment, development, and evaluation (GRADE). MAIN OUTCOMES AND MEASURES: The primary outcome measure was pain. Pain and disability outcomes were converted to a common 0 to 100 scale, with effects greater than 20 points considered clinically important. RESULTS: Of 20 included RCTs of opioid analgesics (with a total of 7925 participants), 13 trials (3419 participants) evaluated short-term effects on chronic low back pain, and no placebo-controlled trials enrolled patients with acute low back pain. In half of these 13 trials, at least 50% of participants withdrew owing to adverse events or lack of efficacy. There was moderate-quality evidence that opioid analgesics reduce pain in the short term; mean difference (MD), -10.1 (95% CI, -12.8 to -7.4). Meta-regression revealed a 12.0 point greater pain relief for every 1 log unit increase in morphine equivalent dose (P = .046). Clinically important pain relief was not observed within the dose range evaluated (40.0-240.0-mg morphine equivalents per day). There was no significant effect of enrichment study design. CONCLUSIONS AND RELEVANCE: For people with chronic low back pain who tolerate the medicine, opioid analgesics provide modest short-term pain relief but the effect is not likely to be clinically important within guideline recommended doses. Evidence on long-term efficacy is lacking. The efficacy of opioid analgesics in acute low back pain is unknown.
IMPORTANCE: Opioid analgesics are commonly used for low back pain, however, to our knowledge there has been no systematic evaluation of the effect of opioid dose and use of enrichment study design on estimates of treatment effect. OBJECTIVE: To evaluate efficacy and tolerability of opioids in the management of back pain; and investigate the effect of opioid dose and use of an enrichment study design on treatment effect. DATA SOURCES: Medline, EMBASE, CENTRAL, CINAHL, and PsycINFO (inception to September 2015) with citation tracking from eligible randomized clinical trials (RCTs). STUDY SELECTION: Placebo-controlled RCTs in any language. DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted data and assessed risk of bias. Data were pooled using a random effects model with strength of evidence assessed using the grading of recommendations assessment, development, and evaluation (GRADE). MAIN OUTCOMES AND MEASURES: The primary outcome measure was pain. Pain and disability outcomes were converted to a common 0 to 100 scale, with effects greater than 20 points considered clinically important. RESULTS: Of 20 included RCTs of opioid analgesics (with a total of 7925 participants), 13 trials (3419 participants) evaluated short-term effects on chronic low back pain, and no placebo-controlled trials enrolled patients with acute low back pain. In half of these 13 trials, at least 50% of participants withdrew owing to adverse events or lack of efficacy. There was moderate-quality evidence that opioid analgesics reduce pain in the short term; mean difference (MD), -10.1 (95% CI, -12.8 to -7.4). Meta-regression revealed a 12.0 point greater pain relief for every 1 log unit increase in morphine equivalent dose (P = .046). Clinically important pain relief was not observed within the dose range evaluated (40.0-240.0-mg morphine equivalents per day). There was no significant effect of enrichment study design. CONCLUSIONS AND RELEVANCE: For people with chronic low back pain who tolerate the medicine, opioid analgesics provide modest short-term pain relief but the effect is not likely to be clinically important within guideline recommended doses. Evidence on long-term efficacy is lacking. The efficacy of opioid analgesics in acute low back pain is unknown.
Authors: Brent A Metfessel; Michelle D Mentel; Amy Phanel; Mary Ann Dimartino; Mureen Allen; Samuel Ho Journal: Pharmacoeconomics Date: 2019-03 Impact factor: 4.981
Authors: Tie P Yamato; Chris G Maher; Bruno T Saragiotto; Christina Abdel Shaheed; Anne M Moseley; Chung-Wei Christine Lin; Bart Koes; Andrew J McLachlan Journal: Br J Clin Pharmacol Date: 2017-08-11 Impact factor: 4.335
Authors: Crystian B Oliveira; Chris G Maher; Rafael Z Pinto; Adrian C Traeger; Chung-Wei Christine Lin; Jean-François Chenot; Maurits van Tulder; Bart W Koes Journal: Eur Spine J Date: 2018-07-03 Impact factor: 3.134
Authors: Ruchir N Karmali; Christopher Bush; Sudha R Raman; Cynthia I Campbell; Asheley C Skinner; Andrew W Roberts Journal: Pharmacoepidemiol Drug Saf Date: 2019-12-18 Impact factor: 2.890
Authors: Donna M Urquhart; Anita E Wluka; Maurits van Tulder; Stephane Heritier; Andrew Forbes; Chris Fong; Yuanyuan Wang; Malcolm R Sim; Stephen J Gibson; Carolyn Arnold; Flavia M Cicuttini Journal: JAMA Intern Med Date: 2018-11-01 Impact factor: 21.873